CRNX Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals has a net margin of -26807.2% compared to Crinetics Pharmaceuticals's net margin of -111.65%. Crinetics Pharmaceuticals's return on equity of -32.07% beat Ionis Pharmaceuticals's return on equity of -100.15%.

Crinetics Pharmaceuticals has a consensus price target of $70.38, signalling upside risk potential of 113.13%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $58.30 which suggests that it could grow by 38.26%. Given that Crinetics Pharmaceuticals has higher upside potential than Ionis Pharmaceuticals, analysts believe Crinetics Pharmaceuticals is more attractive than Ionis Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.254, which suggesting that the stock is 74.553% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.230, suggesting its less volatile than the S&P 500 by 77.021%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $361K, which are smaller than Ionis Pharmaceuticals quarterly revenues of $131.6M. Crinetics Pharmaceuticals's net income of -$96.8M is higher than Ionis Pharmaceuticals's net income of -$146.9M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 8.98x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -26807.2% compared to Crinetics Pharmaceuticals's net margin of -49.65%. Crinetics Pharmaceuticals's return on equity of -32.07% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Crinetics Pharmaceuticals has a consensus price target of $70.38, signalling upside risk potential of 113.13%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Crinetics Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Crinetics Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.254, which suggesting that the stock is 74.553% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $361K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Crinetics Pharmaceuticals's net income of -$96.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -26807.2% compared to Crinetics Pharmaceuticals's net margin of --. Crinetics Pharmaceuticals's return on equity of -32.07% beat Oragenics's return on equity of --.

Crinetics Pharmaceuticals has a consensus price target of $70.38, signalling upside risk potential of 113.13%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than Crinetics Pharmaceuticals, analysts believe Oragenics is more attractive than Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.254, which suggesting that the stock is 74.553% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $361K, which are larger than Oragenics quarterly revenues of --. Crinetics Pharmaceuticals's net income of -$96.8M is lower than Oragenics's net income of -$2.2M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -26807.2% compared to Crinetics Pharmaceuticals's net margin of --. Crinetics Pharmaceuticals's return on equity of -32.07% beat Theriva Biologics's return on equity of --.

Crinetics Pharmaceuticals has a consensus price target of $70.38, signalling upside risk potential of 113.13%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Crinetics Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.254, which suggesting that the stock is 74.553% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $361K, which are larger than Theriva Biologics quarterly revenues of --. Crinetics Pharmaceuticals's net income of -$96.8M is lower than Theriva Biologics's net income of -$4.3M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.